Continuum Advisory LLC Has $30,000 Stock Holdings in The Clorox Company (NYSE:CLX)

Continuum Advisory LLC increased its holdings in shares of The Clorox Company (NYSE:CLX) by 300.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 184 shares of the company’s stock after purchasing an additional 138 shares during the quarter. Continuum Advisory LLC’s holdings in Clorox were worth $30,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Catalyst Capital Advisors LLC acquired a new position in shares of Clorox in the 3rd quarter valued at about $54,000. Raymond James & Associates lifted its position in Clorox by 32.8% in the 2nd quarter. Raymond James & Associates now owns 267,632 shares of the company’s stock worth $36,524,000 after buying an additional 66,149 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Clorox by 8.6% during the 2nd quarter. AQR Capital Management LLC now owns 287,277 shares of the company’s stock valued at $39,121,000 after buying an additional 22,676 shares during the period. Los Angeles Capital Management LLC grew its holdings in shares of Clorox by 5.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 191,919 shares of the company’s stock valued at $31,266,000 after acquiring an additional 10,149 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Clorox by 371.4% in the second quarter. Assenagon Asset Management S.A. now owns 96,969 shares of the company’s stock worth $13,233,000 after acquiring an additional 76,397 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Price Performance

Shares of NYSE:CLX opened at $164.68 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.00 and a debt-to-equity ratio of 11.08. The business has a 50 day moving average price of $163.63 and a 200 day moving average price of $151.21. The company has a market cap of $20.38 billion, a price-to-earnings ratio of 57.35, a PEG ratio of 3.08 and a beta of 0.42. The Clorox Company has a twelve month low of $127.60 and a twelve month high of $171.37.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.50. The business had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.64 billion. Clorox had a net margin of 4.78% and a return on equity of 316.08%. Clorox’s quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the company posted $0.49 earnings per share. Research analysts predict that The Clorox Company will post 6.85 earnings per share for the current year.

Clorox Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 29th will be given a dividend of $1.22 per share. This represents a $4.88 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Wednesday, January 29th. Clorox’s dividend payout ratio is currently 170.03%.

Wall Street Analyst Weigh In

CLX has been the topic of a number of recent research reports. Citigroup boosted their target price on Clorox from $165.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, September 6th. TD Cowen raised Clorox from a “sell” rating to a “hold” rating and boosted their price target for the company from $155.00 to $170.00 in a research note on Wednesday, November 6th. Jefferies Financial Group raised shares of Clorox from a “hold” rating to a “buy” rating and raised their price objective for the company from $174.00 to $187.00 in a research report on Tuesday, October 1st. Evercore ISI decreased their target price on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating for the company in a research report on Monday, October 14th. Finally, Barclays raised their price target on shares of Clorox from $137.00 to $139.00 and gave the company an “underweight” rating in a report on Friday, November 1st. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $155.00.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.